Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Takeda Pharmaceutical Co ADR (NYSE: TAK) closed at $15.46 up 2.38% from its previous closing price of $15.1. In other words, the price has increased by $2.38 from its previous closing price. On the day, 2.63 million shares were traded. TAK stock price reached its highest trading level at $15.545 during the session, while it also had its lowest trading level at $15.3775.
Ratios:
For a deeper understanding of Takeda Pharmaceutical Co ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.58 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.93. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 1.36. In the meantime, Its Debt-to-Equity ratio is 0.65 whereas as Long-Term Debt/Eq ratio is at 0.61.
On March 16, 2023, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $20. Cowen Upgraded its Market Perform to Outperform on July 19, 2022, whereas the target price for the stock was revised from $21 to $24.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 09 ’25 when Lauren Rusckowski Duprey bought 29,619 shares for $14.22 per share.
Teresa Marie Bitetti bought 87,023 shares of TAK for $1,242,688 on Dec 05 ’25. On Dec 04 ’25, another insider, Giles Richard Platford, who serves as the President, Plasma-Derived Ther of the company, bought 58,421 shares for $14.31 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TAK now has a Market Capitalization of 51447029760 and an Enterprise Value of 4535009411072. As of this moment, Takeda’s Price-to-Earnings (P/E) ratio for their current fiscal year is 196.19, and their Forward P/E ratio for the next fiscal year is 25.16. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.59. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.65 while its Price-to-Book (P/B) ratio in mrq is 1.01. Its current Enterprise Value per Revenue stands at 1.027 whereas that against EBITDA is 3.984.
Stock Price History:
The Beta on a monthly basis for TAK is 0.06, which has changed by 0.14916289 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, TAK has reached a high of $15.69, while it has fallen to a 52-week low of $12.80. The 50-Day Moving Average of the stock is 9.15%, while the 200-Day Moving Average is calculated to be 5.56%.
Shares Statistics:
For the past three months, TAK has traded an average of 2.86M shares per day and 3044440 over the past ten days. A total of 3.16B shares are outstanding, with a floating share count of 3.16B. Insiders hold about 0.00% of the company’s shares, while institutions hold 2.71% stake in the company. Shares short for TAK as of 1764288000 were 11381864 with a Short Ratio of 3.98, compared to 1761868800 on 8865714. Therefore, it implies a Short% of Shares Outstanding of 11381864 and a Short% of Float of 0.36000002.
Dividends & Splits
According to the company, the forward annual dividend rate for TAK is 0.32, from 198.0 in the trailing year. Against a Trailing Annual Dividend Yield of 13.112582. The stock’s 5-year Average Dividend Yield is 4.67.
Earnings Estimates
Analysts are recommending an EPS of between $73.97 and $73.97 for the fiscal current year, implying an average EPS of $73.97. EPS for the following year is $122.17, with 1.0 analysts recommending between $122.17 and $122.17.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $1.21T this quarter.It ranges from a high estimate of $1.26T to a low estimate of $1.16T. As of. The current estimate, Takeda Pharmaceutical Co ADR’s year-ago sales were $1.14TFor the next quarter, 5 analysts are estimating revenue of $1.08T. There is a high estimate of $1.13T for the next quarter, whereas the lowest estimate is $1.03T.
A total of 12 analysts have provided revenue estimates for TAK’s current fiscal year. The highest revenue estimate was $4.58T, while the lowest revenue estimate was $4.45T, resulting in an average revenue estimate of $4.51T. In the same quarter a year ago, actual revenue was $580.36BBased on 15 analysts’ estimates, the company’s revenue will be $4.53T in the next fiscal year. The high estimate is $4.65T and the low estimate is $4.38T.
